Envoy Medical Stock Price, News & Analysis

Envoy Medical (NASDAQ: COCH) received a positive listing determination from the Nasdaq Hearings Panel on October 27, 2025, allowing continued listing while the company addresses compliance with Nasdaq Listing Rule 5550(b)(2).

The Panel cited Envoy Medical's recent equity capital raises and debt extinguishment, which together substantially increased stockholders' equity, and the FDA's approval to advance the fully implanted Acclaim cochlear implant clinical trial to its final stage. The company noted over 28 million shares outstanding and higher trading volume since the trial expansion announcement.

The Panel set a compliance deadline of February 23, 2026; Envoy Medical said it will provide timely updates on progress.

Envoy Medical (NASDAQ: COCH) closed a registered direct offering on October 9, 2025, selling 3,007,524 Class A shares at $1.33 per share for gross proceeds of approximately $4.0 million before fees. In a concurrent private placement, Envoy issued unregistered warrants to purchase up to 9,022,572 Class A shares at an exercise price of $1.33 per share; those warrants are exercisable immediately and expire 24 months after the registration statement effective date. H.C. Wainwright acted as exclusive placement agent. Net proceeds are intended for working capital and general corporate purposes. The company cautioned there is no assurance the warrants will be exercised for cash.

Envoy Medical (NASDAQ: COCH) announced a registered direct offering of 3,007,524 shares at $1.33 per share to raise approximately $4.0 million in gross proceeds, and a concurrent private placement of unregistered warrants to purchase up to 9,022,572 shares at an exercise price of $1.33. The warrants are exercisable immediately and expire 24 months after the registration statement effective date. The offering is expected to close on or about October 9, 2025, with H.C. Wainwright serving as placement agent. Net proceeds are intended for working capital and general corporate purposes.

Envoy Medical (NASDAQ: COCH) received FDA approval on October 7, 2025 to expand its pivotal trial for the fully implanted Acclaim cochlear implant to the final stage based on promising three-month data from the first 10 patients.

All 10 participants reached the three-month milestone with no serious adverse events or unanticipated device effects. The company now expects full enrollment by early 2026, has moved timelines up 3–6 months, and reduced anticipated capital needs by $10–$15 million.

Envoy Medical (NASDAQ:COCH), a hearing health company specializing in fully implanted hearing solutions, has announced its participation in the upcoming American Academy of Otolaryngology Head and Neck Surgery (AAO-HNSF) conference. The event will take place on October 11th-14th, 2025 in Indianapolis, IN.

During the conference, the company will conduct individual meetings with implanting surgeons at booth #1108 to discuss recent product developments. Interested attendees can schedule meetings via info@envoymedical.com.

Envoy Medical (NASDAQ: COCH), a hearing health company, has closed its previously announced registered direct offering, raising $2.5 million through the sale of 1,908,402 shares of Class A common stock at $1.31 per share.

The company also conducted a concurrent private placement of unregistered warrants to purchase up to 5,725,206 shares at an exercise price of $1.31 per share. If fully exercised, these warrants could provide additional gross proceeds of $7.5 million. The warrants will be exercisable after stockholder approval and expire 24 months thereafter.

H.C. Wainwright & Co. served as the exclusive placement agent, and Envoy Medical plans to use the net proceeds for working capital and general corporate purposes.

Envoy Medical (NASDAQ: COCH) is advancing commercialization plans for its breakthrough Acclaim® fully implanted cochlear implant while its FDA pivotal trial progresses successfully. The trial has reached significant milestones with all patients completing three-month follow-ups with no serious adverse events, and six-month follow-ups now underway.

The company plans to establish 30-40 clinical sites upon FDA approval, focusing on excellence and strong foundation building. The Acclaim device, which received FDA Breakthrough Device Designation in 2019, is targeting PMA submission in 2027. Envoy Medical aims to tap into an underserved market segment of individuals who haven't adopted traditional hearing loss treatments.

Envoy Medical (NASDAQ: COCH), a hearing health company, has announced a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The company will issue 1,908,402 shares of Class A common stock at $1.31 per share.

Additionally, in a concurrent private placement, Envoy will issue unregistered warrants to purchase up to 5,725,206 shares at an exercise price of $1.31 per share. If these warrants are fully exercised, the company could receive additional gross proceeds of approximately $7.5 million. H.C. Wainwright & Co. is serving as the exclusive placement agent, with the offering expected to close around September 23, 2025.

Envoy Medical (NASDAQ: COCH) has been granted European Patent No. 4338791 for its innovative cochlear implant technology, effective September 17, 2025. The patent specifically covers systems and methods for compensating for variability in middle ear sensors using analog and digital signals.

This patent adds to Envoy Medical's recent patent acquisitions in the United States, Australia, and Hong Kong. The technology relates to their investigational Acclaim® Cochlear Implant, which uniquely eliminates external microphones and hardware by leveraging the natural ear, potentially transforming treatment for severe to profound sensorineural hearing loss.